Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Dilutive issuance
confidence 75%
filed 2026-08-17
The 6-K discloses the closing of a secondary offering by a selling shareholder of 28.1 million ordinary shares, with 15.4 million shares sold publicly at $39.35 per share and 12.8 million shares repurchased by the Company via redemption. While the offering itself is by the selling shareholder (not a primary issuance by the Company), the Company's concurrent share redemption and cancellation of 12.8 million shares represents a capital transaction material to investors. The net effect involves significant share activity and capital deployment (~$500 million redemption amount), though the public offering by the selling shareholder does not directly dilute existing shareholders in the traditional sense.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-17
Item 8.01
DynaResource announced a non-brokered private placement of units at $0.45 per unit to raise $3.0 million (up to $6.4 million with warrant exercise) to existing stockholders. The offering comprises common shares and warrants, representing a dilutive equity issuance. The company has received an advance commitment of $851,250, though completion remains subject to definitive documentation. This is a material capital-raising event typical of small-cap issuers under Item 3.02 (Unregistered Sales of Equity Securities), disclosed here under Item 8.01.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-17
Turn Therapeutics entered into securities purchase agreements on August 14, 2026 to issue and sell 135,000 shares of common stock at $10.00 per share for $1.35 million aggregate gross proceeds in a private placement relying on Section 4(a)(2) and Regulation D exemptions. This is a classic unregistered equity issuance to accredited investors that dilutes existing shareholders and raises capital, fitting the dilutive_issuance category. The company also granted registration rights to the investors, further evidencing the nature of this transaction.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-17
Item 1.01
Singularity Future Technology entered into a securities purchase agreement to sell 21,520,803 shares of common stock at $1.394 per share for approximately $30 million in a private placement to non-U.S. persons under Regulation S. This unregistered equity issuance will significantly dilute existing shareholders and represents a material capital-raising event.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-08-17
EX-99.1
DEFSEC announced a private placement of 1,951,219 common shares (or pre-funded warrants in lieu) at CAD$2.84 per share, plus common share purchase warrants, generating approximately CDN$5.54 million in gross proceeds. The securities are unregistered under the U.S. Securities Act and being sold pursuant to an exemption, with a registration rights agreement for future resale. This is a classic dilutive equity issuance that would materially affect shareholder ownership and is a strong signal of capital-raising activity typical of small- and mid-cap issuers.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-17
Item 3.02
The Company issued one share of Series B Preferred Stock to Ximing Huang in an unregistered offering relying on Section 4(a)(2) exemption. The preferred stock carries material voting and economic rights, representing a significant capital structure change.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-17
The filing discloses a private placement of 933,064 shares of common stock, 1,360,544 pre-funded warrants, and 4,587,216 series E and F warrants in an unregistered offering under Section 4(a)(2) and Regulation D. The transaction raises approximately $3.4 million in gross proceeds with potential additional proceeds of $6.7 million upon warrant exercise. Company insiders, including the CEO and CFO, participated in the offering, purchasing approximately $2.4 million of securities. This is a classic dilutive equity issuance by a small-cap company raising capital through warrants and pre-funded warrants.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-17
Item 3.02
Daré Bioscience announced a registered direct offering of 4,379,581 shares of common stock (or pre-funded warrants) at $1.37 per share, generating $6.0 million in gross proceeds, plus concurrent private placement of Series A and Series B warrants. The press release explicitly states the Series A and Series B warrants are being offered under Section 4(a)(2) of the Securities Act and Regulation D as an unregistered private placement. This is a classic dilutive equity issuance combining registered and unregistered securities to raise capital.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-17
MicroVision entered into a securities purchase agreement on August 14, 2026, to issue 6,800,000 shares of common stock together with 6,800,000 warrants at $2.50 per unit, raising approximately $17.0 million in gross proceeds ($15.6 million net). This is a registered public offering of equity securities with warrants, disclosed under Item 1.01 (Entry into a Material Definitive Agreement). The offering closed on August 17, 2026, and represents a dilutive equity issuance material to investors assessing the company's capital structure and ownership.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 85%
filed 2026-08-17
Guardian Metal Resources announced the exercise of warrants over 3,989,027 new ordinary shares at 40 pence per share, raising £1,595,610.80. This represents a dilutive issuance of equity securities that increases the company's share count from approximately 194.8 million to 198.8 million shares. The warrant exercise is material to investors as it affects ownership dilution and the company's capital structure.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-08-17
EX-99.1
NuRAN Wireless closed a C$7.6 million private placement of Series A convertible preferred shares (1,788,233 shares at C$4.25 per share) convertible into common shares at C$5.00 per share, plus warrants (200,000 A warrants and 1,588,233 B warrants). The financing, structured to satisfy Nasdaq listing requirements, involved settlement of approximately C$3.85 million of convertible debenture debt and C$738,704 of other liabilities in preferred shares, with approximately C$3 million in new cash proceeds, creating significant dilution to existing common shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-08-17
Item 3.02
The Company issued unregistered Units and underlying securities issuable upon conversion of the promissory note to the Sponsor, representing a dilutive private placement with registration rights and transfer restrictions typical of SPAC financing arrangements.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-14
Item 1.01
Ultra Clean Holdings entered into an at-the-market (ATM) offering sales agreement on August 14, 2026, authorizing the sale of up to $400 million of common stock through multiple sales agents. ATM offerings are a form of dilutive equity issuance that signal capital-raising activity and potential shareholder dilution. The material definitive agreement establishing this program is a core disclosure event for equity investors.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-14
Item 1.01
EDAP TMS entered into an underwriting agreement on August 11, 2026 for a public offering of 8,425,000 ADSs at $4.75 per share, with expected net proceeds of approximately $37.1 million. This is a registered public offering of equity securities that will dilute existing shareholders. While technically a registered offering (not an unregistered private placement), the core event is the issuance of a material amount of new equity capital, which is material to investors assessing the company's capital structure and ownership dilution.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-14
Item 8.01
Outlook Therapeutics entered into an underwriting agreement on August 12, 2026 for a public offering of 55,555,556 shares of common stock and accompanying warrants at $0.99 per share, with estimated gross proceeds of approximately $55.0 million. This is a registered public offering of equity securities that will dilute existing shareholders, fitting the dilutive_issuance category. While technically a registered offering (not unregistered), the core event—issuance of a substantial number of new equity securities to raise capital—aligns with the dilutive_issuance taxonomy, which captures material equity capital raises at small- and mid-cap issuers.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-14
Item 3.02
The Company issued 24,649 C-LTIP Units (convertible to OP Units and ultimately redeemable for Class A Common Stock) on August 13, 2026, in partial satisfaction of the Manager's base management fee and executive compensation obligations. The issuance was unregistered, relying on Section 4(a)(2) and Regulation D exemptions. This is a dilutive equity issuance to service management fees and executive compensation, materially affecting shareholder ownership and voting power.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-14
Vuzix entered into an Open Market Sales Agreement with Jefferies on August 14, 2026, establishing an at-the-market offering program for up to $100,000,000 of common stock. This is a dilutive equity issuance under an ATM program, which is material to investors as it signals potential capital raising and shareholder dilution. The filing explicitly discloses the sales agreement, commission structure (3.0%), and prospectus supplement filed under Rule 424(b).
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-14
Item 1.01
PSQ Holdings entered into a securities purchase agreement for a private placement of 361,385 shares of Class A common stock at $3.60 per share, generating $1.3 million in gross proceeds. The transaction is exempt from registration under Section 4(a)(2) and Regulation D Rule 506, with purchasers including company directors represented as accredited investors.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-08-14
EX-99.1
This is an at-the-market (ATM) sales agreement executed on August 14, 2026, authorizing Satellos Bioscience to issue and sell up to $50,000,000 of common shares through Leerink Partners LLC. The agreement explicitly permits sales "at market prices prevailing at the time of sale" and references an effective Registration Statement filed August 11, 2026. This is a dilutive equity issuance that would materially affect existing shareholders through potential share dilution and capital raising activity.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-08-14
EX-99.6
Standard Lithium established an at-the-market (ATM) equity program permitting issuance of up to US$50 million of common shares from treasury to the public at the company's discretion under a shelf prospectus. The company has previously sold US$36 million under a prior ATM program and intends to continue raising capital through this mechanism, creating dilution risk for existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-14
Item 1.01
Delek Logistics Partners entered into an underwriting agreement on August 12, 2026 to sell 4,000,000 common units at $50.00 per unit, with an additional 30-day option for 600,000 units. This is a registered public offering of equity securities (common units representing limited partner interests) that will dilute existing unitholders. The transaction is material to investors as it represents a significant capital raise and dilution event.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-14
Item 8.01
The Company entered into an at-the-market (ATM) offering agreement with Jefferies to sell up to $150 million of common stock. This is a dilutive equity issuance under an ATM program, which is a material capital-raising activity that would affect investor assessment of share dilution and the company's financing strategy. The filing explicitly discloses the Sales Agreement, the maximum offering amount, and intended use of proceeds for commercialization and clinical trials.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-14
Item 7.01
Delek Logistics closed a public offering of 4,600,000 common units (limited partner interests) at $50.00 per unit, raising approximately $220.8 million in gross proceeds. This is a registered public offering of equity securities that dilutes existing unitholders; notably, the controlling shareholder Delek Holdings did not participate, causing its ownership to decline from 63.0% to 58.0%. This is a material capital-raising event typical of dilutive equity issuances disclosed under Item 7.01 (Regulation FD Disclosure).
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-14
Item 3.02
Interactive Strength issued 205,000 shares of Common Stock in exchange for Series A Preferred shares and promissory note principal balances on August 10 and 12, 2026. The filing explicitly discloses this under Item 3.02 (Unregistered Sales of Equity Securities) and notes reliance on Section 3(a)(9) exemption. This represents a material dilutive issuance to existing shareholders, with the exchange shares issued at prices ranging from $3.42 to $3.58 per share, increasing outstanding shares from approximately 1.4 million to 1.6 million shares.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-08-14
The Company entered into a securities purchase agreement on August 13, 2026, to sell 12,000,000 American Depositary Shares at $0.45 per ADS, generating approximately $5.4 million in gross proceeds. This is a registered direct offering of equity securities to certain purchasers, which constitutes a dilutive issuance. The disclosure explicitly references incorporation into the Form F-3 registration statement, confirming this is a material capital-raising transaction that would affect investor assessment of ownership dilution and the company's financial position.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-08-14
Item 1.01
The Company entered into an inducement letter agreement on August 14, 2026, whereby warrant holders exercise existing warrants at a reduced price ($1.20 vs. original $2.33–$3.32) in exchange for new unregistered warrants to purchase 6,015,308 shares at $0.95 per share. This is a classic dilutive private placement structure: the Company issues new equity securities (New Warrants and Placement Agent Warrants) in an unregistered offering under Section 4(a)(2), generating approximately $3.6 million in gross proceeds. The issuance of unregistered equity securities and the significant dilution (doubling the warrant shares outstanding) are hallmarks of a dilutive issuance material to investors.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-08-14
The Company is issuing 728,484 Class A ordinary shares to settle US$557,289.87 in accounts payable owed by its subsidiary WTP. The issuance represents 12.28% of outstanding shares at a price (US$0.765) that is 85% of the closing Nasdaq price, constituting a dilutive equity issuance to settle debt. This is a material capital event affecting existing shareholders' ownership percentage.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-14
Item 1.01
HeartBeam entered into an At-The-Market (ATM) equity offering agreement on August 14, 2026, authorizing the sale of up to $25 million in common stock through Titan Partners Securities LLC. ATM offerings are a form of registered direct equity issuance that can be dilutive to existing shareholders. The filing explicitly references the shelf Registration Statement (Form S-3) and prospectus supplement, confirming this is a registered offering of equity securities that would materially affect investor assessment of capital structure and dilution risk.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 94%
filed 2026-08-14
Item 1.01
Dyadic International completed a registered direct offering of 3,625,000 shares at $0.795 per share combined with a concurrent private placement of 3,625,000 warrants to purchase additional shares, generating approximately $2.9 million in gross proceeds. This dilutive capital raise combines registered and unregistered equity securities and materially dilutes existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-08-14
Clean Energy Technologies entered into a securities purchase agreement with Pacific Pier Capital II, LP to issue a convertible promissory note with principal amount of $178,410 for net funding of $143,000.80. The Note is convertible into common stock at 85% of the lowest 10-day VWAP, with an Exchange Cap of 2,000,000 shares pending shareholder approval. This is a dilutive equity issuance (convertible debt) raising capital through an unregistered private placement under Section 4(a)(2), which is material to investors as it signals potential equity dilution and capital-raising pressure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-14
The filing discloses a private placement of 8,462,027 shares of common stock (or pre-funded warrants in lieu thereof) together with warrants to purchase an additional 16,924,054 shares, raising approximately $4.0 million in gross proceeds. Item 1.01 describes entry into a material definitive securities purchase agreement, and Item 3.02 explicitly addresses unregistered sales of equity securities under Section 4(a)(2) and Regulation D. This is a classic dilutive equity issuance by a small-cap biotechnology company raising capital through a private placement.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-14
Item 3.02
The Company issued 1,433,927 shares of Class A common stock to Liquidity Event Partners in reliance on Section 4(a)(2) exemption from registration, constituting an unregistered equity issuance. This is a material dilutive event for shareholders, particularly significant given the Company's recent IPO (May 19, 2026) and the substantial share count involved. The disclosure is properly filed under Item 3.02, which governs unregistered sales of equity securities.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-14
Item 3.02
In connection with the Redx acquisition, Skye is issuing unregistered equity securities comprising approximately $125 million in aggregate gross proceeds from a PIPE Financing (~$68M), Series A Financing (~$36M), and an Equity Line Facility warrant ($5M), issued under Section 3(a)(10) and Section 4(a)(2) exemptions. The concurrent financing will result in new investors owning approximately 48.45% of the combined company post-closing.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-14
Item 8.01
Zentalis entered into an underwriting agreement to issue and sell 23,000,000 shares of common stock at $3.50 per share, with an additional 3,450,000-share option granted to underwriters. This is a registered public offering of equity securities generating approximately $75.1 million in net proceeds. While technically registered (via Form S-3), the scale and dilutive impact to existing shareholders make this a material capital-raising event that would affect a reasonable investor's assessment of ownership dilution and the company's financing strategy.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-08-14
Item 8.01
RadNet filed a prospectus supplement to register 34,069 shares of common stock for resale by See-Mode Sellers as payment for milestone conditions under a Share Purchase Agreement. This represents a dilutive equity issuance to former acquisition targets, which materially affects shareholder equity and voting power. While the shares are being registered for resale rather than newly issued, the disclosure centers on the registration of shares to be issued as acquisition consideration, fitting the dilutive_issuance category.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-08-13
Item 3.02
Vireo Growth issued approximately 3,004,751 subordinate voting shares as consideration in the PharmaCann acquisition, representing approximately $48.7 million in equity consideration in a transaction exempt from Securities Act registration under Section 4(a)(2) and Regulation D.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-08-13
EX-99.4
Vertical Aerospace amended and restated its Securities Purchase Agreement with YA II PN, Ltd. on August 12, 2026, for the sale of up to $250 million in Series A Convertible Preferred Shares convertible into Ordinary Shares in a private placement structured with multiple closings.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-13
Item 8.01
Delek Logistics announced the pricing of an underwritten public offering of 4,000,000 common units at $50.00 per unit, with an additional 600,000-unit option granted to underwriters. This is a registered public offering of equity securities that will dilute existing unitholders' ownership; the parent company Delek Holdings' stake will decline from 63.0% to approximately 58.0%. The filing explicitly states the offering is made pursuant to an effective shelf registration statement, and the press release was issued in accordance with Rule 134 under the Securities Act.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-13
Item 3.02
Lithium Americas issued common shares and convertible debentures to YA II PN, Ltd. pursuant to a Purchase Agreement, relying on Section 4(a)(2) exemption from registration. The issuance of equity and equity-linked securities constitutes a dilutive capital raise material to investors assessing ownership structure and shareholder dilution.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-13
Veea Inc. entered into an At Market Issuance Sales Agreement (ATM Agreement) with Roth Capital Partners on August 13, 2026, authorizing the sale of up to $4,353,000 in common stock shares through an at-the-market offering under an existing Form S-3 registration statement. This is a classic dilutive equity issuance that would materially affect existing shareholders through potential dilution and is disclosed under Item 1.01 (Entry into a Material Definitive Agreement).
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 90%
filed 2026-08-13
Item 1.01
Zoomcar entered into securities purchase agreements on July 27, 2026, issuing 498 Series A Convertible Preferred Shares and 498 Warrants (exercisable for 9.96 million common shares) in a private placement under Section 4(a)(2) and Regulation D Rule 506(c), with up to $5 million in units plus a $5 million overallotment option. The offering includes unregistered sales of Units, Preferred Shares, Warrants, and Placement Agent Warrants, with significant potential dilution to existing shareholders through conversion and warrant exercise rights.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-13
Item 1.01
CapsoVision entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald for an at-the-market offering program permitting sale of up to $100 million in common stock, representing a material capital-raising mechanism that will dilute existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-08-13
Item 7.01
The filing discloses Rocket Lab's entry into an equity distribution agreement (ATM program) with an aggregate offering price of $1,944,369,826 in common stock. While the company intends to use proceeds to fund the Iridium acquisition and reduce debt, the core disclosure is the establishment of a new equity issuance facility that permits substantial dilution to existing shareholders. The press release explicitly states this is a "replacement" ATM program carrying forward unsold amounts, and the company "may offer and sell" shares at market prices, making this a dilutive equity issuance material to investors assessing capital structure and ownership dilution.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-08-12
Item 8.01
American Express closed the sale of 1,600 Depositary Shares representing Series E Preferred Shares on August 12, 2026, pursuant to an underwriting agreement, creating a new preferred equity security with fixed-rate dividend obligations.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-08-12
EX-99.1
The exhibit discloses a private placement of 5,828,342 special warrants closed on July 30, 2026, for aggregate gross proceeds of approximately US$25 million. The special warrants will automatically convert into common shares and common share purchase warrants, creating significant dilution to existing shareholders. This is a classic dilutive equity issuance under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D, and the magnitude (US$25M) and structure (warrant-based conversion) make it material to investors.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 94%
filed 2026-08-12
Item 3.02
APPlife Digital Solutions issued a $170,000 convertible promissory note to an accredited investor under Regulation D. The note is convertible into common stock at a 35% discount to the lowest trading price during the preceding 20 trading days, with conversion rights commencing six months after issuance, resulting in equity dilution upon conversion.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-08-12
Item 8.01
Lucid registered for resale approximately 75.7 million shares of Class A Common Stock (51.7 million from conversion of Series C Convertible Preferred Stock and 24.0 million issued to SMB/Uber subsidiary) plus 55,000 shares of Series C Convertible Preferred Stock. Although the filing emphasizes "no new shares will be issued," the registration of these previously-issued private placement shares for resale creates material dilution risk to existing shareholders. The involvement of major investors (Saudi Arabia's Public Investment Fund via Ayar and Uber Technologies via SMB) and the substantial share count make this a material capital event affecting shareholder value.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-12
Item 1.01
Ryman Hospitality Properties entered into an underwriting agreement on August 10, 2026, to issue 5,100,000 shares of common stock at $117.00 per share in a registered public offering, with underwriters exercising a 30-day option for an additional 765,000 shares on August 11, 2026. The offering closed on August 12, 2026, generating approximately $658 million in net proceeds. This is a material registered equity issuance that dilutes existing shareholders and represents a significant capital-raising event.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-12
Item 1.01
OLB Group entered into an Equity Distribution Agreement with Maxim Group LLC on August 7, 2026, establishing an "at-the-market offering" (ATM) program to sell up to $1,600,000 of common stock shares. This is a classic dilutive equity issuance under Rule 415, where the company retains discretion over timing and volume but commits to a registered offering program that will dilute existing shareholders. The prospectus supplement filed on August 7, 2026, registered the shares for sale, making this a material capital-raising event typical of small- and mid-cap issuers.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-12
Item 8.01
Intel announced and entered into an underwriting agreement for a $20 billion registered public offering of approximately 210.5 million shares of common stock at $95 per share, with underwriters holding a 30-day option to purchase an additional 31.6 million shares. Net proceeds of approximately $19.7 billion are intended for general corporate purposes including capital expenditures and working capital.
View raw filing on EDGAR →